Highlights

  • On November 6, 2026, Braveheart and Hengrui presented 52-week open-label extension data for BHB-1893 in obstructive HCM.
  • The third quarter net loss was $26,495 thousand, or $0.51 per share, compared with $59,118 thousand, or $10.05 per share.
  • Cash, cash equivalents and investments were $503.5 million at September 30, 2026; management expects funding into 2029.
  • Braveheart sold 24,437,500 shares at $18.00 per share in its August 7, 2026 IPO, for gross proceeds of $439.9 million.

Braveheart Bio, Inc. (NASDAQ:BRVE) shares were trading at USD 19.01 on November 17, 2026, down 2.46%, with a relative Volume at time of 1.96. The clinical-stage biopharmaceutical company completed its initial public offering on August 7, 2026, presented BHB-1893 data at the AHA Scientific Sessions on November 6, and filed its third quarter report on November 10.

Braveheart is a Delaware corporation incorporated in May 2024 and headquartered in San Francisco, California. It is a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for obstructive HCM and non-obstructive HCM. It holds exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan under a license with Jiangsu Hengrui Pharmaceuticals. It has no products approved for sale and no product revenue. Its fiscal year ends December 31.

AHA Scientific Sessions Presentations

On November 6, 2026, Braveheart and Hengrui presented clinical and preclinical data for BHB-1893 at the American Heart Association Scientific Sessions. In the 52-week open-label extension of Hengrui's Phase 2 trial in obstructive HCM, all 42 patients from the 12-week core period rolled over. The company reported that 79% (33/42) of patients had a Valsalva LVOT-G below 30 mmHg at Week 52, and that mean peak oxygen uptake improved by 2.7 mL/kg/min and the KCCQ-CSS score improved by 17.3 points from baseline.

The company stated that no severe or serious treatment-emergent adverse events occurred while patients received study drug. Two patients had a transient site-measured LVEF below 50% and resumed treatment at a lower dose. In a Phase 2 trial in 84 patients with non-obstructive HCM, LVEF below 50% was observed in four of 56 BHB-1893-treated patients, each of whom returned to 50% or greater after dose reduction. The company expects 52-week data from that trial's extension in the first half of 2027.

Third Quarter Results

For the quarter ended September 30, 2026, Braveheart reported Research and Development expense of $17,542 thousand, compared with $9 thousand a year earlier. General and administrative expense was $12,607 thousand, compared with $508 thousand, and included stock-based compensation of $7.8 million, of which $6.1 million related to liability-classified modified executive restricted stock awards. In-process research and development expense was zero, compared with $58,770 thousand.

Total operating expenses were $30,149 thousand, compared with $59,287 thousand, and interest income was $3,712 thousand. The net loss was $26,495 thousand, or $0.51 per share, compared with $59,118 thousand, or $10.05 per share. For the nine months, the net loss was $55,763 thousand, and the accumulated Deficit was $122.4 million.

Balance Sheet and Capital

Cash, cash equivalents and investments were $503.5 million at September 30, 2026, including cash and cash equivalents of $121,291 thousand. On August 7, 2026, the company completed its IPO of 24,437,500 shares at $18.00 per share, with gross proceeds of $439.9 million and net proceeds of approximately $404.4 million. Net cash used in Operating Activities for the nine months was $46.5 million, compared with $0.7 million.

The company stated that its cash, cash equivalents and investments should fund operating expenses and Capital expenditures into 2029 and for at least the next twelve months, and that it will need additional financing to support continuing operations. Under the Hengrui license, Hengrui is eligible for up to $23.0 million in technology transfer and development milestones, up to $1.0 billion in commercial milestones and tiered royalties of 5% to 10%.

Development Plans

The company is enrolling LIONHEART-HCM, a Phase 3 trial comparing BHB-1893 with metoprolol in adults with symptomatic obstructive HCM, and expects an interim analysis in the second half of 2027. It plans to start TRUEHEART-HCM and NOBLEHEART-HCM in the first half of 2027.